Cargando…

Progressive neurodegeneration following spinal cord injury: Implications for clinical trials

OBJECTIVE: To quantify atrophy, demyelination, and iron accumulation over 2 years following acute spinal cord injury and to identify MRI predictors of clinical outcomes and determine their suitability as surrogate markers of therapeutic intervention. METHODS: We assessed 156 quantitative MRI dataset...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziegler, Gabriel, Grabher, Patrick, Thompson, Alan, Altmann, Daniel, Hupp, Markus, Ashburner, John, Friston, Karl, Weiskopf, Nikolaus, Curt, Armin, Freund, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890610/
https://www.ncbi.nlm.nih.gov/pubmed/29514946
http://dx.doi.org/10.1212/WNL.0000000000005258
_version_ 1783312895994494976
author Ziegler, Gabriel
Grabher, Patrick
Thompson, Alan
Altmann, Daniel
Hupp, Markus
Ashburner, John
Friston, Karl
Weiskopf, Nikolaus
Curt, Armin
Freund, Patrick
author_facet Ziegler, Gabriel
Grabher, Patrick
Thompson, Alan
Altmann, Daniel
Hupp, Markus
Ashburner, John
Friston, Karl
Weiskopf, Nikolaus
Curt, Armin
Freund, Patrick
author_sort Ziegler, Gabriel
collection PubMed
description OBJECTIVE: To quantify atrophy, demyelination, and iron accumulation over 2 years following acute spinal cord injury and to identify MRI predictors of clinical outcomes and determine their suitability as surrogate markers of therapeutic intervention. METHODS: We assessed 156 quantitative MRI datasets from 15 patients with spinal cord injury and 18 controls at baseline and 2, 6, 12, and 24 months after injury. Clinical recovery (including neuropathic pain) was assessed at each time point. Between-group differences in linear and nonlinear trajectories of volume, myelin, and iron change were estimated. Structural changes by 6 months were used to predict clinical outcomes at 2 years. RESULTS: The majority of patients showed clinical improvement with recovery stabilizing at 2 years. Cord atrophy decelerated, while cortical white and gray matter atrophy progressed over 2 years. Myelin content in the spinal cord and cortex decreased progressively over time, while cerebellar loss decreases decelerated. As atrophy progressed in the thalamus, sustained iron accumulation was evident. Smaller cord and cranial corticospinal tract atrophy, and myelin changes within the sensorimotor cortices, by 6 months predicted recovery in lower extremity motor score at 2 years. Whereas greater cord atrophy and microstructural changes in the cerebellum, anterior cingulate cortex, and secondary sensory cortex by 6 months predicted worse sensory impairment and greater neuropathic pain intensity at 2 years. CONCLUSION: These results draw attention to trauma-induced neuroplastic processes and highlight the intimate relationships among neurodegenerative processes in the cord and brain. These measurable changes are sufficiently large, systematic, and predictive to render them viable outcome measures for clinical trials.
format Online
Article
Text
id pubmed-5890610
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-58906102018-04-10 Progressive neurodegeneration following spinal cord injury: Implications for clinical trials Ziegler, Gabriel Grabher, Patrick Thompson, Alan Altmann, Daniel Hupp, Markus Ashburner, John Friston, Karl Weiskopf, Nikolaus Curt, Armin Freund, Patrick Neurology Article OBJECTIVE: To quantify atrophy, demyelination, and iron accumulation over 2 years following acute spinal cord injury and to identify MRI predictors of clinical outcomes and determine their suitability as surrogate markers of therapeutic intervention. METHODS: We assessed 156 quantitative MRI datasets from 15 patients with spinal cord injury and 18 controls at baseline and 2, 6, 12, and 24 months after injury. Clinical recovery (including neuropathic pain) was assessed at each time point. Between-group differences in linear and nonlinear trajectories of volume, myelin, and iron change were estimated. Structural changes by 6 months were used to predict clinical outcomes at 2 years. RESULTS: The majority of patients showed clinical improvement with recovery stabilizing at 2 years. Cord atrophy decelerated, while cortical white and gray matter atrophy progressed over 2 years. Myelin content in the spinal cord and cortex decreased progressively over time, while cerebellar loss decreases decelerated. As atrophy progressed in the thalamus, sustained iron accumulation was evident. Smaller cord and cranial corticospinal tract atrophy, and myelin changes within the sensorimotor cortices, by 6 months predicted recovery in lower extremity motor score at 2 years. Whereas greater cord atrophy and microstructural changes in the cerebellum, anterior cingulate cortex, and secondary sensory cortex by 6 months predicted worse sensory impairment and greater neuropathic pain intensity at 2 years. CONCLUSION: These results draw attention to trauma-induced neuroplastic processes and highlight the intimate relationships among neurodegenerative processes in the cord and brain. These measurable changes are sufficiently large, systematic, and predictive to render them viable outcome measures for clinical trials. Lippincott Williams & Wilkins 2018-04-03 /pmc/articles/PMC5890610/ /pubmed/29514946 http://dx.doi.org/10.1212/WNL.0000000000005258 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Ziegler, Gabriel
Grabher, Patrick
Thompson, Alan
Altmann, Daniel
Hupp, Markus
Ashburner, John
Friston, Karl
Weiskopf, Nikolaus
Curt, Armin
Freund, Patrick
Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title_full Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title_fullStr Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title_full_unstemmed Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title_short Progressive neurodegeneration following spinal cord injury: Implications for clinical trials
title_sort progressive neurodegeneration following spinal cord injury: implications for clinical trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890610/
https://www.ncbi.nlm.nih.gov/pubmed/29514946
http://dx.doi.org/10.1212/WNL.0000000000005258
work_keys_str_mv AT zieglergabriel progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT grabherpatrick progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT thompsonalan progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT altmanndaniel progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT huppmarkus progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT ashburnerjohn progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT fristonkarl progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT weiskopfnikolaus progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT curtarmin progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials
AT freundpatrick progressiveneurodegenerationfollowingspinalcordinjuryimplicationsforclinicaltrials